Objective If IL-2 and IFN-? are united,perhaps we may see a more significant antitumor effect.A fusion gene of IL-2 and IFN-? was designed and constructed by DNA engineering.Methods CEA promotor、IL-2cDNA and IFN-?cDNA were obtained by PCR and RT-PCR.SDS-PAGE was used to examine the results;pcDNA-IL-2、pcDNA-IFN-?、pCEA-IL-2/ IFN-?、pEGFP-IL-2/ IFN-? were transfected to CEA high expression cell line(Lovo)by use of liposome.The fusion protein expression was examined by fluorescence microscope and Western blotting.Results IL-2/ IFN-? fusion gene can be expressed in tumor cells.Its expression is more obvious in CEA high expressed cells(Lovo),and can be located in cell plasma.Conclusion The fusion gene can be expressed in plasma of CEA high expressed cell lines.It may have a new anti-tumor effects.

Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus,but clinical practices in the management of diabetic dyslipidemia are still not satisfactory in China.The cornerstone of treatment for diabetic dyslipidemia consists of therapeutic lifestyle change and statins.Recent guidelines emphasize aggressive low density lipoprotein-cholesterol control with statins.However,intensive statin therapy may increase the risk of myopathy and diabetes.Therefore,it is important to consider its risk benefit ratio in individual patients.The additional benefit of statins in combination with other hypolipidemic drugs on cardiovascular risk needs verifying by further investigation.

Bnip3,a kind of mitochondrion apoptosis gene,belongs to the Bcl-2 gene family and BH3-only subfamily.It is one of the downstream response factors of hypoxia inducible factor (HIF).Bnip3 can induce cell apoptosis and autophagy under the oxygen deficit condition.Many studies show that Bnip3 is closely related to the occurrence,development and treatment of tumors.Molecular targeting treatment aimed at Bnip3 combined with chemoradiotherapy has preferable application foreground in tumor therapy.

Objective To investigate the effects of different target concentrations of remifentanil when combined with propofol on BIS in patients undergoing neurosurgery. Methods Fifteen ASA Ⅰ or Ⅱ patients, aged 18-64 yr, weighing 50-85 kg, scheduled for intracranial surgery, were involved in this study. The patients received propofol by target controlled infusion (TCI) at a target effect site concentration (Ce) of 3μg/ml. TCI of remifentanil was started after TCI of propofol reached the preset Ce and Ce of remifentanil was increased step by step from 2 ng/ml to 3, 4, 5, 6, 7 and 8 ng/ml. Invasive BP, MAP, HR and BIS were continuously monitored and recorded when remifentanil reached the each preset Ce. Vecuronium 0.1 mg/kg was injected iv when Ce of remifentanil reached 5 ng/ml, and then the patients were intubated and mechanically ventilated 3 min later. The changes in BP, MAP, HR and BIS were recorded. When HR < 50 bpm and/or MAP < 60 mm Hg, TCI of remifentanil was stopped and iv atropine or ephedrine was given. Results BIS was significantly decreased after TCI of remifentanil when propofol reached 3 μg/ ml compared with the baseline value ( P < 0.05 or 0.01). BIS was significantly decreased when Ce of remifentanil ≥6 ng/ml compared with that when propofol reached 3 μg/ml ( P < 0.05 or 0.01) .Conclusion Low-concentration of remifentanil when combined with propofol has no effect on BIS, but when Ce of remifentanil≥ 6 ng/ml, BIS is obviously decreased.

OBJECTIVE: To explore the anti-tumor and immunologic enhancement effects of Xiangling capsule.METHODS: The tumor-inhibition experiment was conducted in vivo in accordance with the screening criteria of anti-tumor drugs.Mice were treated with cyclophosphamide to induce hypoimmunity model.The effect of Xiangling capsule on mice was tested by determining leukocyte count,thymus index,spleen index,and the activity of NK cells.RESULTS: Xiangling capsules at different concentration showed inhibition on the growth of mice-transplanted tumor S180,H22 hepatomas and Lewis lung carcinoma with inhibition rates of 44.8%,52.2 %,and 43.3%,respectively(P

In the past decade, liquid chromatography-mass spectrometry has undergone rapid development in clinical laboratory medicine.Benefiting from the high sensitivity and specificity, as well as the capability of multi-component analysis in the single run, such technology is regarded as an excellent alternative to conventional immunoassays towards newborn screening for the genetic diseases, therapeutic drug monitoring and endocrine hormones detection.With the continuing progress in expertise-training, quality assurance and methodology standardization, it could be expected that liquid chromatography-mass spectrometry would become a dynamic and crucial part for routine clinical applications in the near future.

Objective:To investigate the expression of latent membrane protein-1(LMP-1),NET-1,and vascular endothelial growth factor(VEGF)in non-keratin nasopharyngeal carcinoma(NK-NPC)and its clinical significance.Methods :Sixty biopsy specimens from pathologically-confirmed NK-NPC patients,who were treated in the Affilitated Hospital of Nantong University from May 1999 to May 2003,were included in the present study.Using immunohistochemical techniques (Envison two-step),we examined the expression of LMP-1,NET-1 and VEGF protein in the specimens.The relationship between their expression and elnicopathological parameters and the prognosis was anayzed.Ten specimens of chronic nasopharyngitis served as control.Results:(1)The positive rates of LMP-1,NET-1 and VEGF in NK-NPC were significantly higher than those in the chronic nasopharyngitis(P0.05).(3)NET-1 and VEGF expression in NK-NPC specimens were positively correlated with lymph node metastasis and distant metastasis(P

Textbooks are the base of teaching.The physiology textbooks used in medical education was compared between China and the United States.Guyton and Hall Textbook of Medical Physiology was chosen as the major representative of the United States.The overall framework, the selection and arrangement of the contents, the application of tables and pictures, and the relationship between basic medicine and clinical medicine were discussed.This paper may provide some information for remodeling of specialized course system and teaching contents of physiology, especially for improving the constructive quality of textbooks in the future.

Objective To analyze clinical Value of serum homocysteine(Hcy)and cystatin C(Cys C) in patients with cerebral in‐farction .Methods From August 2010 to December 2014 ,our hospital 118 patients with cerebral infarction and 62 healthy subjects for the study were divided into the control group and the observation group .The observation group was further divided into light , medium and heavy groups .Test results for the two groups were related to the study of serum homocysteine and Cys C were ana‐lyzed separately and compared between two groups of Hcy levels Cys C contact with cerebral infarction .Results Serum Hcy ,Cys C levels significantly higher in the observation group than that of control group ,differences were statistically significant(P<0 .05);The serum Hcy ,Cys C of patients with severe cerebral infarction group were significantly higher than that of light and medium cer‐ebral infarction group;Serum Hcy ,Cys C levels of patients with medium cerebral infarction group were also significantly higher than the light cerebral infarction group ,differences were statistically significant(P<0 .05) .Conclusion The serum Hcy and Cys C has important clinical value of detecting the disease assessment and treatment of patients with cerebral infarction .

Dyslipidemia is one of the major risk factors for cardiovascular disease in elderly,but clinical practices in the management of elderly dyslipidemia are still not satisfactory.The cornerstone of treatment for elderly dyslipidemia consists of therapeutic lifestyle change and statins.Recent guidelines emphasize aggressive low density lipoprotein-cholesterol control with statins.However,intensive statin therapy may increase the risk of myopathy and diabetes.Therefore,it is important to consider risk benefit ratio in individual patients.The additional benefit of statins in combination with other hypolipidemic drugs on cardiovascular risk still needs verifying by further investigation.